The HLA system and the clinical response to treatment with chlorpromazine.
A group of 33 schizophrenic patients were typed for HLA-SD antigens and their qualitative clinical responses to chlorpromazine therapy determined. A highly significant positive correlation was found between response to chlorpromazine and HLA-AI positive, while HLA-A2 positive subjects showed a significant negative correlation to chlorpromazine treatment. In a second group of 17 patients the clinical response to chlorpromazine were evaluated quantitatively, by WPRS, in HLA-AI positive and HLA-AI negative patients. There were no pre-treatment differences in the scores. After treatment the scores of positive patients were significantly lower, indicating that they responded to a greater degree. Since the frequency of HLA-AI in hebephrenic patients is higher than that in other schizophrenics this may explain our earlier finding that hebephrenics, as a group, respond better to chlorpromazine than do other schizophrenics.
D001007:Anxiety / Q000188:drug therapy; D001665:Binding Sites; D002462:Cell Membrane / Q000276:immunology; D002746:Chlorpromazine / Q000378:metabolism / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy; D006680:HLA Antigens / Q000032:analysis*; D006649:Histocompatibility Antigens / Q000032:analysis*; D006801:Humans; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy / Q000276:immunology; D012563:Schizophrenia, Paranoid / Q000188:drug therapy / Q000276:immunology
D006680:HLA Antigens; D006649:Histocompatibility Antigens; D002746:Chlorpromazine